Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021
- PMID: 35758873
- PMCID: PMC9278220
- DOI: 10.1093/cid/ciac526
Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021
Abstract
In April 2021, we assessed mRNA vaccine effectiveness (VE) in the context of a COVID-19 outbreak in a skilled nursing facility. Among 28 cases, genomic sequencing was performed on 4 specimens on 4 different patients, and all were classified by sequence analysis as the Beta (B.1.351) variant. Adjusted VE among residents was 65% (95% confidence interval: 25-84%). These findings underscore the importance of vaccination for prevention of COVID-19 in skilled nursing facilities.
Keywords: SARS-CoV-2; skilled nursing facility; vaccine effectiveness.
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.
Conflict of interest statement
Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
Investigation of a Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) Variant Outbreak Among Residents of a Skilled Nursing Facility and Vaccine Effectiveness Analysis: Maricopa County, Arizona, June-July 2021.Clin Infect Dis. 2022 Aug 24;75(1):e20-e26. doi: 10.1093/cid/ciac240. Clin Infect Dis. 2022. PMID: 35413107 Free PMC article.
-
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34437519 Free PMC article.
-
Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.Clin Microbiol Infect. 2022 Apr;28(4):614.e5-614.e7. doi: 10.1016/j.cmi.2021.12.013. Epub 2021 Dec 24. Clin Microbiol Infect. 2022. PMID: 34958917 Free PMC article.
-
Vaccine Effectiveness during Outbreak of COVID-19 Alpha (B.1.1.7) Variant in Men's Correctional Facility, United States.Emerg Infect Dis. 2022 Jul;28(7):1313-1320. doi: 10.3201/eid2807.220091. Emerg Infect Dis. 2022. PMID: 35731137 Free PMC article. Review.
-
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review.Hum Vaccin Immunother. 2022 Nov 30;18(5):2045857. doi: 10.1080/21645515.2022.2045857. Epub 2022 Mar 3. Hum Vaccin Immunother. 2022. PMID: 35240940 Free PMC article. Review.
Cited by
-
Epidemiology of COVID-19 outbreaks in aged care facilities during postvaccine period: a systematic review and meta-analysis.BMJ Open. 2024 Mar 14;14(3):e073555. doi: 10.1136/bmjopen-2023-073555. BMJ Open. 2024. PMID: 38485480 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous